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The effect of RORa expression on the 
development of biological malignancy  
of urinary bladder cancer
AbsTRAcT
Background: Morbidity and mortality relating to urinary bladder cancer have remained largely unchanged 
for many years. Similarly, the five-year survival rate in this disease has not improved considerably. New 
developments in individualized therapy necessitate the search for novel factors that could predict the 
development of malignancy in UBC. In this study, we provide the first evidence that the expression of ROR 
alpha transcription factor influences the development of malignancy in UBC. 
Materials and methods: 105 patients with stage pT1-pT4 urothelial bladder carcinoma who underwent 
cystectomy were included in the study. 4 µm tissue samples were stained immunohistochemically with 
a polyclonal anti-RORa antibody. The expression of RORa by the tumor cells (TCs) was assessed by 
counting TCs with a cytoplasmic and/or nuclear staining for RORa per 1000 TCs. The association between 
the extent of RORa expression and non-classic differentiation, tumor advancement (pT), grade (G) and 
regional lymph node spread was analyzed. 
Results: The cytoplasmic expression of RORa was detected in near all analyzed tumor samples (104/105). 
The extent of RORa expression was significantly higher in tumors which were more malignant with more 
propensity for non-classic differentiation and lymph node metastasis. We noted a lower percentage of 
TCs expressing RORa in poorly differentiated tumors (G3), compared to tumors moderately and higher 
differentiated (G1/G2).
Conclusions: Our results suggest that RORa may play a significant role in the progression of urinary 
bladder cancer. RORa has a broad spectrum of regulatory activity relating to cell and tissue differentia-
tion the mechanism of which is not fully understood. This study represents another step in the process 
of understanding the mechanisms of RORa regulation and highlights its potential role as a therapeutic 
target in urothelial bladder cancer. 
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Introduction
Urinary bladder cancer (UBC) is one of the most fre-
quently diagnosed cancers in the world [1] with a four-
fold higher incidence rate in men [1–4] as well as an 
increasing prevalence of established risk factors such 
as smoking, overweight, physical inactivity, and chang-
ing reproductive patterns associated with urbanization 
and economic development. Based on GLOBOCAN 
estimates, about 14.1 million new cancer cases and 
8.2 million deaths occurred in 2012 worldwide. Over the 
years, the burden has shifted to less developed coun-
tries, which currently account for about 57% of cases 
and 65% of cancer deaths worldwide. Lung cancer is 
the leading cause of cancer death among males in both 
more and less developed countries, and has surpassed 
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breast cancer as the leading cause of cancer death 
among females in more developed countries; breast 
cancer remains the leading cause of cancer death 
among females in less developed countries. Other 
leading causes of cancer death in more developed 
countries include colorectal cancer among males and 
females and prostate cancer among males. In less 
developed countries, liver and stomach cancer among 
males and cervical cancer among females are also 
leading causes of cancer death. Although incidence 
rates for all cancers combined are nearly twice as high 
in more developed than in less developed countries in 
both males and females, mortality rates are only 8% to 
15% higher in more developed countries. This disparity 
reflects regional differences in the mix of cancers, which 
is affected by risk factors and detection practices, and/or 
the availability of treatment. Risk factors associated with 
the leading causes of cancer death include tobacco 
use (lung, colorectal, stomach, and liver cancer. UBC is 
typically diagnosed in women in more advanced stages 
and appears to be more aggressive [4, 5]. Morbidity 
and mortality relating to UBC have not changed signifi-
cantly for many years. Likewise, five-year survival rates 
have not improved [4, 6]. Urothelial bladder carcinoma 
constitutes approximately 90% cases of UBC. Early 
detection of UBC allows for endoscopic removal of the 
tumor with transurethral resection of bladder tumor 
(TURBT) [7]including basic surgical techniques such as 
the obturator nerve block. Important basic surgical skills 
required for complete TURBT in non-muscle invasive 
bladder cancer are: (i. However, cancer recurrence is 
frequent recurrence rates of 50% one year after surgical 
treatment [8]. Disease progression in 10–20% of those 
cases qualifies the patient for radical cystectomy [9]. 
In order to reduce the number of radical cystectomies 
and to personalize treatment regimens, it is necessary 
to search for new prognostic and predictive markers 
of malignancy in UBC. RORa (retinoid acid-related 
orphan receptor alpha; RORA; NR1F1) belongs to the 
nuclear receptor family of transcription factors called 
retinoid-related orphan receptors which includes also 
RORb and RORg. Changes in the expression levels 
of nuclear receptors are observed in different types 
of cancers including melanoma, breast cancer or 
liver cancer [10–13]. RORs have a modular structure 
including a DNA binding domain (DBD) and a ligand 
binding domain (LBD) which are distinctive for nuclear 
receptors. RORs regulate transcription through DBD 
binding to specific regulatory DNA sequences (ROR 
Response Elements) in target genes. However, ROR 
Response Elements are not specific only for RORs. Oth-
er nuclear receptors including transcription repressors 
may compete for the binding sites of the regulatory 
DNA sequences in an antagonistic manner [14–17]. 
The presence of LBDs allows for the modulation of 
ROR activity by various molecules acting as agonists or 
antagonists which respectively enhance or suppress the 
effect of RORs on the transcription of target genes [18, 
19]. Accordingly, RORs became an important research 
area in the biology of cancer due to their potential to 
become new targets for therapeutic strategies. Some 
studies demonstrate that RORs play critical roles in 
the regulation of a variety of physiological processes 
[20]. The orphan nuclear receptor ROR alpha has 
been shown to be involved in the control of cell growth 
and differentiation [21]. There are reports of the role 
of RORs in breast cancer [22], melanoma [10, 23], 
hepatocellular carcinoma [24], and colorectal cancer 
[25]. However, we are not aware of studies involving 
the role of RORs expression in UBC. In this study, we 
provide the first evidence that the expression of ROR 
alpha transcription factor influences the development 
of pT1-pT4 UBC as defined by histological and clinical 
indicators of malignancy including tumor advancement 
(pT), grade (G), a number of non-classic differentiation 
types (NDN) and lymph node spread (pN). 
Materials and methods
Study group
105 patients with pT1-pT4 urothelial bladder cancer 
who underwent radical cystectomy/cystoprostatectomy 
in from Oncology Centre-Prof. Franciszek Łukaszczyk 
Memorial Hospital in Bydgoszcz between 2011 and 
2014 was included in the study. The median age of 
patients was 65 years. The mean age was 65 years 
(64 years in women and 65 years in men). The detailed 
characteristics of the study group are presented in Table 
1. The study was approved by the Bioethics Committee 
at the Nicolaus Copernicus University in Torun, Collegi-
um Medicum in Bydgoszcz, Poland (No: KB 587/2018).
The preparation and assessment of H&E stained 
samples
Tissue sections were fixed in 10% buffered formalin 
and embedded in paraffin blocks according to a standard 
protocol. Tumor advancement (pT stage), histological 
malignancy (G), frequency of non-classic differentiation 
(ND) and the number of non-classic differentiation types 
(NDN) was assessed as previously described [26–29]. 
Staging and histological type of tumors were assessed 
according to the WHO TNM classification [30].
The preparation and assessment of 
immunostained samples
Immunohistochemical staining was performed 
on 4 µm tissue sections with the use of polyclonal 
anti-RORa. Antigen retrieval was performed in a high 
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Table 1. Patient clinical and pathological characteristics
Feature Number of cases
Sex
    Female
    Male
24
81
Grading (G)
    1
    2
    3
2
46
57
pT
    pT1
    pT2a
    pT2b
    pT3a
    pT3b
    pT4a
12
13
11
8
30
31
pN
    0
    1
    2
    3
62
14
27
2
NDN
    0
    1
    2
    3
    4
    5
    6
31
28
25
12
6
2
1
pH buffer (EnVision Flex+ Target Retrieval Solution, 
High pH: Bufor Tris/EDTA, pH 9; Dako) in PT Link 
(Dako) pre-treatment module. Following the blocking 
of intracellular peroxidase (EnVision Flex, Dako) and 
blocking of non-specific binding sites (Block Surface 
Blocker, Candor Bioscience GmbH) the tissue samples 
were incubated with anti-RORa antibody overnight at 
4°C. Afterwards, the samples were incubated with the 
secondary antibody (EnVision FLEX/HRP, Dako) for 
30 minutes. The staining was visualized after a 5-min-
ute incubation with EnVision FLEX DAB+ Chromogen, 
Dako, followed by a hematoxylin staining. The sam-
ples were assessed using a Nikon Eclipse 80i light 
microscope. A positive and negative sample of a skin 
section was included in each staining cycle, with the 
omission of the RORa antibody for the negative control. 
The expression of RORa by the tumor cells (TCs) was 
assessed by counting TCs with a cytoplasmic and/or 
nuclear staining for RORa per 1000 TCs regardless of 
the intensity of the staining.
Statistical analysis
The relationships between TCs expression of RORa 
and variables such as pT, pN, G and NDN were ana-
lyzed using the Mann-Whitney-Wilcoxon test. The statis-
tical analyses were performed using STATISTICA data 
analysis software (version 13, StatSoft, Inc., Tulsa, OK, 
USA). A p-value < 0.05 was considered to be significant.
Results
Cytoplasmic expression of RORa was detected in 
close to all tested tumor samples (104/105) while nu-
clear expression was noted in only 3 cases. 
Expression of RORa and lymph node status (pN)
In the cases of tumors with lymph node involvement 
(n = 43), a higher percentage of TCs expressing RORa 
was observed (Fig. 1CD), compared to non-metastatic 
tumors (n = 62) (Fig. 1AB).
A correlation between the presence of lymph node 
metastases and the extent of ROR positive TCs was 
observed. The percentage of ROR positive TCs was 
significantly higher in tumors presenting lymph node 
metastases (Fig. 2).
Expression of RORa and NDN
The percentage of TCs expressing RORa is higher 
in tumors with non-classic differentiation (Fig. 3).
In tumors with one or more non-classic differentia-
tion types (NDN > 0), the extent of RORa positive TCs 
was significantly higher compared with tumors with the 
classic type of differentiation (NDN = 0) (Fig. 4).
Expression of RORa and grading (G)
We noted a lower percentage of TCs expressing 
RORa in poorly differentiated tumors (G3), compared to 
moderately and higher differentiated tumors (G1 and G2).
RORa expression in neoplastic cells and tumor 
stage (pT)
There was no significant correlation between RORa 
frequency and tumor staging (not shown).
Discussion
A literature review reveals that RORa is a widely dis-
tributed nuclear receptor known for its regulatory activity 
regarding metabolism, inflammation, angiogenesis or 
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Figure 1. Atypical morphology of a non-metastatic tumor in H&E staining (A, 100x) is associated with none or few ROR-
positive tumor cells (B, 40x). A high percentage of ROR-positive TCs (D, 40x) identifies metastatic tumors with atypical 
morphology in H&E staining (C, 40x). Arrows indicate ROR+ TCs
RORa and metastasizing in prl-p-14 tumors
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Figure 2. The percentage of ROR positive TCs was about 
30% higher in metastatic tumors in comparison with non-
metastatic tumors
circadian rhythm [17, 31]. Increasingly, retinoid acid 
receptor-related orphan receptors are being studied 
in the context of cancer-related processes including 
gastric cancer, melanoma or colorectal cancer [32]. 
Fu RD et al. observed that a lowered RORa expression 
was associated with worse survival prognosis in he-
patocellular carcinoma [13]. In our study, RORa was 
weakly expressed (Fig. 1D, Fig. 3D) in every analyzed 
urothelial tumor. A downregulation of RORa expression 
may be related to the process of neogenesis which led 
us to analyze the extent of RORa expression within 
the tumor. We observed that the percentage of TCs 
expressing RORa was notably higher in metastatic 
tumors compared to tumors without the involvement 
of regional lymph nodes (Fig. 2). The gain of the abil-
ity to metastasize is considered to be the last stage 
in the progression of urothelial cancer and identifies 
a highly malignant tumor capable of forming sec-
ondary distant tumor sites [33]. The broad extent of 
weakly-expressed RORa may indicate a deficit of the 
transcription factor or perhaps insufficient efficiency 
of cellular repair systems. We have not found a suf-
ficient explanation of that problem in the available 
literature. Further research aimed at the identification 
of RORa-regulated metabolic pathways that result 
in increased metastasis is necessary. Considering 
the established role of RORa in the processes of cell 
growth and differentiation [34]-beta, and -gamma are 
transcription factors belonging to the steroid hormone 
receptor superfamily. During embryonic development 
RORs are expressed in a spatial and temporal manner 
and are critical in the regulation of cellular differentia-
tion and the development of several tissues. RORalpha 
plays a key role in the development of the cerebel-
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RORa and NDN in pTl-pT4 tumors
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Figure 3. A classic differentiation (A, 100x) is associated with a low frequency of tumor cells expressing ROR (B) (case 
with NDN = 0, 40x). A higher frequency of ROR+ tumor cells (D, 40x) can be observed in tumors with at least one non-
classic differentiation type (C) (case with NDN > 0, 100x)
Figure 4. The percentage of ROR positive TCs was about 
30% higher in NDN > 0 tumors in comparison with tumors 
of only classic type of differentiation
Figure 5. The percentage of ROR positive TCs was about 
20% lower in G3 tumors in comparison with tumors less 
dedifferentiated (G2)
lum particularly in the regulation of the maturation 
and survival of Purkinje cells. In RORalpha-deficient 
mice, the reduced production of sonic hedgehog 
by these cells appears to be the major cause of the 
decreased proliferation of granule cell precursors 
and the observed cerebellar atrophy. RORalpha has 
been implicated in the regulation of a number of other 
physiological processes, including bone formation. 
RORbeta expression is largely restricted to several 
regions of the brain, the retina, and pineal gland. Mice 
deficient in RORbeta develop retinal degeneration that 
results in blindness. RORgamma is essential for lymph 
node organogenesis. In the intestine RORgamma is 
required for the formation of several other lymphoid 
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tissues: Peyer’s patches, cryptopatches, and isolated 
lymphoid follicles. RORgamma plays a key role in the 
generation of lymphoid tissue inducer (LTi, the role 
of RORa warrants investigation in the context of its 
impact on the increased malignant potential of UBC 
and its histological differentiation. Xiong G et al. ob-
served suppression of the invasive capacity of breast 
cancer through RORa [22]. In our study, we showed 
that a large extent of weakly-expressed RORa was 
associated with tumors displaying non-classic types 
of differentiation (Fig. 3CD, Fig. 4) which is a marker of 
increased malignancy in UBC tumors [27, 28]. Thus, 
the influence of RORa on non-classic differentiation 
cannot be dismissed yet it has not been explored in 
the literature to date. Likewise, the results showing 
a correlation between RORa expression and histo-
logical dedifferentiation in UBC are a novel finding. 
The data obtained in this study show a statistically 
significant difference in RORa expression between 
moderately differentiated (G2) and poorly differenti-
ated (G3) tumors. We also demonstrated that lower 
histological malignancy was associated with a higher 
extent of RORa expression (Fig. 5), resulting probably 
from insufficiency of RORa depended on cellular repair 
systems. The biology of UBC is still poorly understood. 
Therefore, research on the mechanisms of promotion 
and progression of UBC is highly necessary. RORa is 
an interesting potential therapeutic target in various 
tumors thanks to its ability to be influenced by various 
agonists and antagonists binding to its ligand binding 
domain [35, 36]. This study reinforces that notion 
demonstrating a potential role of RORa in influencing 
the malignancy of UBC.
conclusions
The observed association between the extent of 
RORa expression and malignancy of urothelial blad-
der carcinoma may suggest an important role of that 
receptor in the progression of UBC. As a transcription 
factor, RORa displays a broad range of regulatory 
effects involving cell and tissue differentiation. The 
mechanisms of regulation by RORa are not yet fully 
understood. This study represents another step in 
the process of understanding those mechanisms and 
highlights the potential role of RORa as a therapeutic 
target in urothelial bladder cancer. 
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